(CercleFinance.com) – Nanobiotix announces that it has completed the dose escalation portion of the phase 1 study evaluating its NBTXR3 in patients with recurrent, inoperable non-small cell lung cancer (NSCLC) likely to be reirradiated.
This completed part of the dose escalation of study 2020-0123 made it possible to determine the recommended dose for phase 2 (RP2D) after determining the feasibility of the injection and observing a favorable safety profile.
The biotech company adds that the dose expansion portion of Phase 1, designed to evaluate additional safety signals and evaluate early signs of effectiveness, is underway.